Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and declining beta-cell function, often leading to chronic hyperglycemia and associated complications. Despite the availability of various pharmacological agents, glycemic control remains suboptimal in a significant proportion of patients, particularly when relying solely on monotherapy or delayed combination strategies. This review explores the current challenges in diabetes management within primary care settings, highlighting the limitations of monotherapy and dual therapy approaches. It emphasizes the role of early, individualized treatment intensification using triple combination therapy involving metformin, dapagliflozin, and sitagliptin. This combination targets complementary pathophysiological pathways - hepatic glucose production, renal glucose reabsorption, and incretin hormone regulation - offering superior glycemic control, reduced risk of hypoglycemia, weight management, and cardiorenal benefits. The SMART-DM framework is introduced as a simplified and actionable approach to guide physicians in optimizing diabetes care. In alignment with global and national clinical guidelines, this review supports the timely adoption of fixed-dose triple therapy to overcome clinical inertia and improve treatment adherence. Additionally, the review discusses evidence from key clinical trials, patient selection considerations, and safety profiles, thereby providing a comprehensive guide for health care practitioners aiming to enhance long-term outcomes in patients with T2DM.